Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Clinical Immunology · Activated PI3K-Delta Syndrome Type 2

Proactive Monitoring and Red Flags

At a Glance

APDS2 needs an individualized monitoring and fever plan because chronic lung disease, serious infections, and lymphoma can develop quietly. Seek prompt care for changing lymph nodes, unexplained fever, night sweats, weight loss, persistent gut symptoms, breathing trouble, or bleeding.

Living with APDS2 requires a shift from reactive care (treating problems as they arise) to proactive surveillance. Because the disease is rare and its risks—such as lung damage and lymphoma—can develop silently, an individualized monitoring plan guided by your symptoms is the most powerful tool you have to protect long-term health [1][2].

Long-Term Outlook and Risks

While APDS2 is a serious condition, understanding the risks allows for better preparation.

  • Leading Risks: The most significant long-term concerns are chronic lung infections and B-cell lymphoma, a type of blood cancer [3][4]. Across large groups of patients, lymphoma and infection are the most common causes of mortality [3].
  • Historical Survival Data: Pooled historical data for APDS (combining types 1 and 2) show a survival rate of approximately 87% at age 20 and 74% at age 30 [5]. It is crucial to understand that these are historical, pooled population estimates, not a personal prognosis. Individual outcomes vary significantly based on how early the disease is caught and managed, and these figures may not reflect outcomes with current targeted treatments [6][7].
  • Lung Health: A subset of patients develop bronchiectasis (permanent airway scarring), making lung monitoring a lifelong priority [4][8].

Recommended Surveillance Strategy

There is no “one-size-fits-all” calendar or universally validated lymphoma-screening protocol for every APDS2 patient. Your doctor will adjust these based on your specific history [1].

Area of Concern Monitoring Tool Typical Approach
Lungs Pulmonary Function Tests (PFTs) & symptom review. Routine clinical assessment [2].
High-Resolution CT Scan of the chest. When clinically indicated (avoiding routine radiation) [8].
Lymphoma Physical exam of lymph nodes and spleen. Regular clinical examination [2].
Complete Blood Count (CBC) and EBV viral load. Individualized (e.g., EBV testing is relevant in specific clinical settings) [2][9].
FDG-PET/CT or MRI. Only if malignancy is suspected [10].
Growth/Gut Growth charts and BMI tracking. Routine checks in children [4].
Gastrointestinal review (diarrhea/pain). Discussed at routine visits [11].

Managing “Scanxiety”

It is normal to feel significant anxiety before scheduled scans or lab tests. Remember that the goal of these tests is to evaluate issues while they are manageable. If a scan shows “stable” findings—even if those findings (like enlarged nodes) are not “normal”—that is often reassuring relative to growth, though stability alone does not replace clinical examination and context [10].

Red Flags and Fever Plan: When to Seek Medical Care

In APDS2, you need a clear, clinician-directed fever and infection action plan. Do not wait for listed signs of sepsis (like confusion or mottled skin) to seek care. A new fever or suspected infection may require same-day or emergency assessment depending on your immune profile. Ask your immunologist for an individualized temperature threshold and an after-hours contact plan.

Routine Monitoring (Mention at next visit)

  • Stable, painless, small swollen glands during a common cold.
  • Mild, familiar fatigue.
  • Occasional loose stools that resolve quickly.

Same-Day Call (Contact your immunologist today)

  • Rapid Change: A lymph node that is growing quickly or becomes painful [12].
  • B-Symptoms: Unexplained fevers, drenching night sweats, or unintentional weight loss [9].
  • New Asymmetry: One side of the neck or armpit is significantly more swollen than the other [12].
  • Persistent Gut Issues: Chronic diarrhea, severe abdominal pain, or blood in the stool [13][9].

Emergency (Call 911 or go to the ER immediately)

  • Respiratory Distress: Difficulty breathing, blue tint to the lips, or using chest muscles to “pull” in air [14].
  • Severe Infection/Sepsis: High fever reaching your personalized threshold, inability to keep fluids down, extreme shivering, or lethargy [14][15].
  • Acute Bleeding: Coughing up blood (hemoptysis) or severe gastrointestinal bleeding [16].
  • Severe Pain: Sudden, agonizing abdominal pain which could indicate a bowel issue called intussusception [13].

Early intervention during these red-flag events is the most effective way to prevent serious complications [1]. Always trust your intuition as a patient or caregiver—if something feels fundamentally different than your usual symptoms, seek care [7].

Common questions in this guide

How often does someone with APDS2 need lung monitoring?
There is no single schedule for everyone with APDS2. Routine visits usually include symptom review and pulmonary function tests, while a high-resolution chest CT is used when clinically indicated; timing depends on the person’s lung history and clinician judgment.
How is lymphoma risk monitored in APDS2?
Clinicians may check the lymph nodes and spleen, review symptoms, and use a complete blood count or EBV viral load testing when appropriate. FDG-PET/CT or MRI is generally reserved for situations in which lymphoma or another cancer is suspected, and there is no universally validated schedule for every patient.
What APDS2 symptoms should prompt a same-day call?
Contact the immunology team the same day if a lymph node grows quickly or becomes painful, or if there are unexplained fevers, drenching night sweats, unintentional weight loss, new one-sided swelling, persistent diarrhea, severe abdominal pain, or blood in the stool.
When should an APDS2 fever be treated as an emergency?
Ask the immunologist in advance for a personal temperature threshold and an after-hours action plan. Call 911 or go to the emergency department for breathing trouble or blue lips, a high fever reaching that threshold with inability to keep fluids down, extreme shivering, or unusual lethargy.
What does a stable scan mean in APDS2?
A stable scan means the findings have not changed, which can be reassuring compared with growth even when the findings are not normal. Stability does not replace a physical examination or other clinical context, so the care team should interpret the result as part of the whole picture.
Can APDS2 cause bronchiectasis?
Repeated or chronic lung infections can lead to bronchiectasis, which is permanent scarring of the airways. Because lung damage can progress silently, lifelong symptom review and lung monitoring may be needed.
What is the long-term outlook for people with APDS2?
Historical studies combining APDS1 and APDS2 reported survival estimates of about 87% at age 20 and 74% at age 30, but these are population estimates rather than an individual prognosis. Outcomes vary with early diagnosis, management, and available treatments, so the care team should interpret risk for each person.

Get notified when new evidence is published on immunodeficiency 132b.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    Spanish Consensus on the Diagnosis and Management of Patients With Activated PI3K Delta Syndrome (APDS).

    Neth O, Alsina L, Rivière JG, et al.

    Journal of investigational allergology & clinical immunology 2025; (35(2)):87-102 doi:10.18176/jiaci.1059.

    PMID: 40028901
  2. 2

    Key outcomes in treatment of activated phosphoinositide 3-kinase delta syndrome: An e-Delphi panel study and responder threshold application.

    Upton JEM, Williams KW, Cant A, et al.

    PloS one 2025; (20(10)):e0333341 doi:10.1371/journal.pone.0333341.

    PMID: 41091701
  3. 3

    Genetic Etiologies and Outcomes in Malignancy and Mortality in Activated Phosphoinositide 3-Kinase Delta Syndrome: A Systematic Review.

    Büsch K, Memmott HL, McLaughlin HM, et al.

    Advances in therapy 2025; (42(2)):752-771 doi:10.1007/s12325-024-03066-7.

    PMID: 39636570
  4. 4

    Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.

    Elkaim E, Neven B, Bruneau J, et al.

    The Journal of allergy and clinical immunology 2016; (138(1)):210-218.e9 doi:10.1016/j.jaci.2016.03.022.

    PMID: 27221134
  5. 5

    Systematic review of mortality and survival rates for APDS.

    Hanson J, Bonnen PE

    Clinical and experimental medicine 2024; (24(1)):17 doi:10.1007/s10238-023-01259-y.

    PMID: 38280023
  6. 6

    Overall survival among patients with activated phosphoinositide 3-kinase delta syndrome (APDS).

    Mahendran M, Upton JEM, Ramasubramanian R, et al.

    Orphanet journal of rare diseases 2025; (20(1)):212 doi:10.1186/s13023-025-03734-z.

    PMID: 40319290
  7. 7

    Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.

    Maccari ME, Wolkewitz M, Schwab C, et al.

    The Journal of allergy and clinical immunology 2023; (152(4)):984-996.e10 doi:10.1016/j.jaci.2023.06.015.

    PMID: 37390899
  8. 8

    Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.

    Coulter TI, Chandra A, Bacon CM, et al.

    The Journal of allergy and clinical immunology 2017; (139(2)):597-606.e4 doi:10.1016/j.jaci.2016.06.021.

    PMID: 27555459
  9. 9

    Case Report: EBV Chronic Infection and Lymphoproliferation in Four APDS Patients: The Challenge of Proper Characterization, Therapy, and Follow-Up.

    Rivalta B, Amodio D, Milito C, et al.

    Frontiers in pediatrics 2021; (9()):703853 doi:10.3389/fped.2021.703853.

    PMID: 34540765
  10. 10

    The Dark Side of Activated Phosphoinositide 3-Kinase-δ Syndrome 2: A Story Rewritten through FDG-PET.

    Catelli A, Nanni C, Mulè R, et al.

    Journal of clinical medicine 2024; (13(8)) doi:10.3390/jcm13082203.

    PMID: 38673479
  11. 11

    Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.

    Maccari ME, Abolhassani H, Aghamohammadi A, et al.

    Frontiers in immunology 2018; (9()):543 doi:10.3389/fimmu.2018.00543.

    PMID: 29599784
  12. 12

    Evaluation of Lymphoproliferative Disease and Increased Risk of Lymphoma in Activated Phosphoinositide 3 Kinase Delta Syndrome: A Case Report With Discussion.

    Pham MN, Cunningham-Rundles C

    Frontiers in pediatrics 2018; (6()):402 doi:10.3389/fped.2018.00402.

    PMID: 30619796
  13. 13

    Activated phosphoinositide 3-kinase δ syndrome caused by PIK3CD mutations: expanding the phenotype.

    Zhao P, Huang J, Fu H, et al.

    Pediatric rheumatology online journal 2024; (22(1)):24 doi:10.1186/s12969-024-00955-7.

    PMID: 38287413
  14. 14

    Epstein-Barr Virus-Positive B-Cell Lymphoproliferative Disorder Complicated by Septic Shock in Activated PI3Kδ Syndrome: A Pediatric Case Report and Literature Review.

    Zhao X, Ming X, Shang Z, et al.

    Case reports in hematology 2026; (2026()):3644513 doi:10.1155/crh/3644513.

    PMID: 42591980
  15. 15

    [Activated phosphoinositide 3-kinase delta syndrome: report of seven cases].

    Liu QH, Peng L, Huang H, et al.

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2024; (26(5)):499-505 doi:10.7499/j.issn.1008-8830.2312065.

    PMID: 38802911
  16. 16

    Case Report: Recurrent pulmonary infections with neck masses: a diagnostic challenge and literature review.

    Zhao L, Zhao J, Lu Y

    Frontiers in medicine 2026; (13()):1807946 doi:10.3389/fmed.2026.1807946.

    PMID: 42040580

This APDS2 monitoring information is for educational purposes only and does not constitute medical advice. Your immunologist should tailor testing and fever instructions to your child or your specific situation; seek emergency care for severe symptoms.